Acrodermatitis continua

L12_PSORI_ACRODERM

psoriasis: An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519972
1. Apply sex-specific rule None	519972
2. Check conditions None	519972
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — L40.2 Hospital discharge: ICD-9 — 6961C Hospital discharge: ICD-8 — 68696 Cause of death: ICD-10 — L40.2 Cause of death: ICD-9 — 6961C Cause of death: ICD-8 — 68696 2 out of 7 registries used, show all original rules.	74
4. Check minimum number of events None	74
5. Include endpoints None	74
6. Filter based on genotype QC (FinnGen only)	72

Control definitions (FinnGen only)

Control exclude: L12_PAPULOSQUAMOUS

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: L40
Name in latin: Acrodermatitis continua (Hallopeau)

NAME	L12_PSORI_ACRODERM
CONTROL_EXCLUDE	L12_PAPULOSQUAMOUS
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	L402
HD_ICD_9	6961C
HD_ICD_8	68696
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	L402
COD_ICD_9	6961C
COD_ICD_8	68696
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Acrodermatitis continua based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	449	266	181
Only index persons	419	250	169
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	55.60	54.91	56.85
Only index persons	55.27	54.78	55.99

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	72	45	27
Unadjusted period prevalence (%)	0.01	0.02	0.01
Median age at first event (years)	55.57	52.55	60.59

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
74: Matched controls
740

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

L40.2

ICD-10 Finland

Acrodermatitis continua

+∞

100.9

D07AD01

ATC

clobetasol; topical

30.1

50.6

L04AX03

ATC

methotrexate; systemic

21.8

41.2

D05BB02

ATC

acitretin; oral

+∞

36.5

D07XC01

ATC

betamethasone; topical

19.4

34.6

D05AX52

ATC

calcipotriol, combinations; topical

63.0

33.4

L40.0

ICD-10 Finland

Psoriasis vulgaris

220.5

28.9

D05AX02

ATC

calcipotriol; topical

153.8

21.9

E0000UV, ,

ATC

14.5

21.7

210

L40.5

ICD-10 Finland

Arthropathic psoriasis

+∞

19.6

M07.3*L40.5

ICD-10 Finland

Other psoriatic arthropathies

216.9

17.3

D07AC01

ATC

betamethasone; topical

7.1

15.7

160

319

Kela drug reimbursment

Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis)

+∞

15.1

E000001, ,

ATC

6.6

14.7

L40.9

ICD-10 Finland

Psoriasis, unspecified

+∞

12.9

L30.9

ICD-10 Finland

Dermatitis, unspecified

5.8

12.6

D07AC13

ATC

mometasone; topical

5.4

12.0

126

L40.3

ICD-10 Finland

Pustulosis palmaris et plantaris

141.1

11.8

L01BA01

ATC

methotrexate; systemic

33.9

11.2

E000003, ,

ATC

13.4

9.9

L30.3

ICD-10 Finland

Infective dermatitis

25.8

9.7

D05AX03

ATC

calcitriol; topical

114.0

9.7

M07.3

ICD-10 Finland

Other psoriatic arthropathies

+∞

9.6

L40.8

ICD-10 Finland

Other psoriasis

+∞

9.6

S91

ICPC

Psoriasis

57.0

8.9

202

Kela drug reimbursment

Connective tissue diseases, rheumatoid arthritis and comparable disease

5.3

8.4

D02AE01

ATC

carbamide; topical

11.4

8.2

E000002, ,

ATC

5.5

7.9

E000006, ,

ATC

9.6

7.6

TQW80

NOMESCO Finland

Local dermatologic skincare

18.9

7.0

NK4XE

NOMESCO Finland

Joint ultrasound examination not elsewhere classified

7.0

6.6

L04AB04

ATC

adalimumab; parenteral

16.2

6.6

D07AB02

ATC

hydrocortisone butyrate; topical

3.4

6.2

134

D01BA02

ATC

terbinafine; oral

3.5

6.1

115

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40760892) CBC W Ordered Manual Differential panel - Blood

280

5.11

9.19

18.9

5.8

—

(3017181) Myelocytes/100 leukocytes in Blood

5.00

7.76

4.9

4.5

0.45

0.57

0.18

(3002179) Metamyelocytes/100 leukocytes in Blood

5.21

7.51

4.8

4.3

0.11

0.93

—

(3000494) Fungus identified in Specimen by Culture

4.39

7.48

2.3

1.3

—

(3025159) Blasts/100 leukocytes in Blood

4.85

6.92

4.9

4.7

0.00

0.06

—

(3021440) Promyelocytes/100 leukocytes in Blood

4.85

6.92

5.2

4.8

0.00

0.06

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

4.36

5.56

1.5

1.4

—

(40766800) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood

14.72

5.21

1.3

1.0

—

(40768443) Skin Pathology biopsy report

6.60

5.00

1.3

1.1

—

(3023420) DNA double strand Ab [Units/volume] in Serum

12.69

4.37

1.1

1.2

—

(3007853) Bacteria identified in Skin by Aerobe culture

3.15

3.70

1.9

1.5

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

8.44

3.64

1.3

1.7

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

5.86

3.64

1.8

1.9

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

5.24

3.36

1.8

2.1

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.73

3.17

2.2

1.7

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

5.82

2.94

1.1

1.3

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

8.82

2.79

1.4

1.2

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

5.03

2.66

1.9

2.5

4.86

5.78

e9/l

—

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

5.03

2.66

1.9

2.5

56.00

65.47

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.57

2.62

1.5

1.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

413

2.29

2.50

6.8

4.1

—

(3022217) INR in Platelet poor plasma by Coagulation assay

259

2.07

2.41

21.3

12.8

1.68

1.20

inr

1.46

(3048929) Epstein Barr virus Ab [Presence] in Serum

3.95

2.21

1.0

1.3

—

(3013707) Erythrocyte sedimentation rate by Westergren method

458

2.23

2.13

10.1

3.9

13.90

11.21

mm/h

0.91

423

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

481

2.31

2.11

13.7

7.2

76.93

77.41

u/l

0.05

453

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.19

2.00

1.8

1.6

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

210

1.92

1.95

4.4

3.0

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

122

2.01

1.79

1.8

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

329

1.83

1.72

7.1

6.1

12.09

10.77

umol/l

0.28

316

(3009508) Creatinine [Moles/volume] in Urine

157

1.89

1.70

2.3

2.8

7.13

7.72

mmol/l

0.30

130

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

102

2.01

1.63

1.6

1.7

—

(3023368) Bacteria identified in Blood by Culture

153

1.84

1.54

5.3

4.2

—

(3002582) Erythrocytes [#/volume] in Urine

189

1.77

1.49

3.9

3.2

13.95

364.73

e6/l

0.54

150

(3031040) Bacteria [#/volume] in Urine by Automated count

399

1.78

1.48

7.5

4.1

—

71.23

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

123

1.86

1.43

1.4

1.7

0.77

0.98

mg/l

0.31

(3018095) Leukocytes [#/volume] in Urine

218

1.73

1.43

6.2

3.9

18.62

85.55

e6/l

1.60

157

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.30

1.39

2.0

1.4

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

1.94

1.39

4.6

2.7

113.73

86.41

ng/l

0.10

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

1.38

0.0

1.5

—

(3042936) Bacteria identified in Isolate by Culture

1.98

1.32

1.9

1.7

—

(3044640) Blood type and Crossmatch panel - Blood

187

1.70

1.29

3.1

2.2

—

(3012516) Albumin [Mass/volume] in Urine

145

1.74

1.25

2.5

3.0

31.16

518.40

mg/l

0.54

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

2.74

1.23

1.8

1.6

—

340.72

—

(3035350) Ketones [Presence] in Urine by Test strip

302

1.62

1.19

5.1

3.7

0.00

estimate

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

2.60

1.17

2.0

2.4

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

148

1.69

1.16

2.1

3.0

3043.47

1525.74

ng/l

0.34

128

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

1.87

1.15

3.3

3.2

1.07

0.90

e6/l

—

(3020682) Albumin/Creatinine [Ratio] in Urine

150

1.66

1.10

3.0

3.6

5.23

8.33

mg/mmol

0.41

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

624

2.11

1.05

25.8

12.6

17.99

23.03

mg/l

0.87

484

(3020630) Protein [Mass/volume] in Serum or Plasma

1.99

1.05

1.4

1.6

67.42

66.14

g/l

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

299

1.56

1.05

6.2

5.6

1.22

mmol/l

0.05

258

(3030467) Casts [#/volume] in Urine by Automated count

161

1.62

1.03

4.4

3.1

0.35

0.39

e6/l

0.03

122

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

135

1.66

1.03

3.8

2.1

—

(3019225) pH of Specimen

1.91

1.01

5.1

4.4

—

(40761536) Microorganisms panel - Urine sediment

1.91

1.01

2.9

3.5

—

(36304419) Bacteria [Presence] in Urine

165

1.57

0.93

4.2

2.8

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.01

0.92

1.5

1.4

—

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

248

1.51

0.92

2.6

2.3

80.96

78.07

nmol/l

0.22

224

(3018418) pH of Serum or Plasma

185

1.53

0.88

2.3

3.9

7.41

7.40

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

214

1.50

0.85

4.0

3.5

16.56

34.32

ng/l

1.00

145

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.84

0.84

2.4

1.4

—

(40768793) Breast Pathology biopsy report

0.00

0.80

0.0

1.3

—

(3009261) Glucose [Presence] in Urine by Test strip

302

1.45

0.80

4.2

3.7

0.00

estimate

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.77

0.76

2.5

1.6

—

(40761535) Cells panel - Urine sediment

1.69

0.69

4.3

2.8

—

(40768797) Stomach Pathology biopsy report

1.60

0.69

1.2

1.4

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

113

1.53

0.68

1.3

40.41

15.48

u/ml

—

(3021601) Nitrite [Presence] in Urine by Test strip

299

1.40

0.68

6.3

5.1

0.00

estimate

—

(40768804) Tissue Pathology biopsy report

243

1.39

0.64

1.8

2.1

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.61

0.0

1.3

—

(40758558) Short blood count panel - Blood

161

1.42

0.61

15.4

7.0

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.60

0.0

1.5

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.60

0.0

1.5

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

1.83

0.60

6.5

5.5

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

1.55

0.59

3.4

3.54

4.41

e6/l

—

(3026008) Bacteria identified in Urine by Culture

181

1.39

0.58

3.9

2.7

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

286

1.35

0.57

3.1

2.4

—

(3007164) IgA [Mass/volume] in Serum or Plasma

127

1.44

0.56

1.5

1.3

3.61

2.25

g/l

—

(4200892) Spirometry reversibility

1.54

0.49

1.1

1.3

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.41

0.0

1.6

—

(3051387) C reactive protein [Mass/volume] in Capillary blood

0.00

0.41

0.0

5.3

—

37.22

—

(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay

0.00

0.41

0.0

2.5

—

0.22

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

115

0.66

0.41

1.5

1.4

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.40

0.0

1.3

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.40

0.0

1.3

—

(3014051) Protein [Presence] in Urine by Test strip

0.00

0.40

0.0

2.1

—

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

1.46

0.40

1.8

2.6

2.22

6.20

ug/l

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.39

0.0

1.4

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.39

0.0

1.4

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.39

0.0

1.4

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.39

0.0

1.4

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

1.32

0.38

4.1

5.9

105.33

103.79

mmol/l

—

(3022145) Colonoscopy Study observation

1.32

0.38

1.4

—

(3003694) ABO and Rh group [Type] in Blood

164

0.75

0.35

1.4

1.6

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

566

1.32

0.34

20.6

12.4

88.78

83.54

ml/min/173m2

1.38

455

(3000991) Gas panel - Venous blood

1.33

0.34

3.0

5.8

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

392

1.23

0.33

3.3

3.0

—

(3041096) Erythrocytes [Presence] in Urine by Automated

179

1.24

0.29

3.4

3.5

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.28

0.28

1.1

3.6

—

(3002385) Erythrocyte distribution width [Ratio]

550

0.82

0.27

31.7

15.5

14.55

15.21

0.55

543

(1761868) Lipid panel - Serum or Plasma

231

0.82

0.27

2.9

2.6

—

(3028026) IgM [Mass/volume] in Serum or Plasma

1.34

0.24

1.8

0.83

1.30

g/l

—

(3013512) EKG study

164

1.21

0.23

3.3

3.5

—

(3019060) Gas panel - Arterial blood

1.30

0.23

7.4

3.6

—

(3024354) Oxygen [Partial pressure] in Venous blood

1.27

0.23

2.6

2.5

4.44

4.56

kpa

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

1.24

0.22

3.2

2.4

—

(40759812) SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(40759844) Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(40759843) Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(40759836) Histone Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(40759849) Smith extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.21

0.0

1.2

—

(40759842) Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.21

0.0

1.2

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.21

0.0

1.2

—

(1616796) Gas panel - Central venous blood

0.00

0.21

0.0

4.1

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.21

0.0

2.6

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.20

0.0

3.7

—

18.61

—

(3000492) Spirometry study

1.17

0.19

1.5

1.3

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.17

0.19

1.8

1.5

—

(36660697) Celiac disease serology panel - Serum

1.23

0.19

1.1

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

139

1.19

0.18

5.0

3.1

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.75

0.18

1.2

1.8

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.20

0.17

16.5

8.0

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

121

1.19

0.16

4.0

5.2

16.34

21.15

—

(3002256) Pathology report gross observation

0.75

0.16

1.2

1.3

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

112

1.19

0.15

2.2

1.5

—

(40761511) CBC panel - Blood by Automated count

647

0.82

0.15

22.8

12.0

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

241

1.12

0.12

4.3

3.6

—

(3044889) 12 lead EKG panel

401

1.11

0.12

3.3

3.7

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.04

0.07

2.1

2.0

—

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

563

0.91

0.07

5.1

4.9

38.59

39.08

mmol/mol

0.22

533

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

1.13

0.06

3.1

2.9

2.47

mmol/l

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

588

0.94

0.02

4.4

4.2

5.99

5.78

mmol/l

0.74

551

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

162

1.06

0.02

2.5

1.6

1.32

1.23

mmol/l

0.20

143

(3019550) Sodium [Moles/volume] in Serum or Plasma

626

0.94

0.01

20.2

13.7

139.27

139.77

mmol/l

0.81

612

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

606

0.95

0.01

4.6

2.63

2.76

mmol/l

0.52

562

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

596

0.95

0.00

5.6

4.1

4.43

4.71

mmol/l

1.26

559

(3021960) Folate [Moles/volume] in Serum or Plasma

145

0.96

0.00

1.3

1.4

19.66

22.86

nmol/l

0.45

125

(3029937) Albumin [Presence] in Urine by Test strip

165

1.04

0.00

4.5

3.8

0.00

estimate

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

155

1.04

0.00

5.0

5.4

2.23

1.86

ug/l

0.21

135

(3023103) Potassium [Moles/volume] in Serum or Plasma

625

1.05

0.00

20.0

13.8

3.89

3.96

mmol/l

1.26

611

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.98

0.00

2.0

1.8

—

(3017569) Oxygen content in Arterial blood

0.00

-0.00

0.0

2.2

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

-0.00

0.0

1.0

—

(3036669) Protein S actual/normal in Platelet poor plasma by Coagulation assay

0.00

-0.00

0.0

1.2

—

89.00

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.1

—

(3045156) Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

-0.00

0.0

3.0

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

-0.00

0.0

1.9

—

(3019497) Choriogonadotropin.beta subunit free [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.4

—

(3040363) Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay

0.00

-0.00

0.0

1.0

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

0.00

-0.00

0.0

1.0

—

(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay

0.00

-0.00

0.0

1.2

—

(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid

0.00

-0.00

0.0

1.1

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

-0.00

0.0

1.2

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.5

—

4.03

—

(3001788) Aldosterone [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

190.67

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

220

1.00

-0.00

2.1

1.7

90.34

99.26

pmol/l

0.34

109

(3041423) Sjogrens syndrome-A extractable nuclear 60kD Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.3

—

(3013201) Beta-2-Microglobulin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

3.20

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

-0.00

0.0

1.0

—

(3030136) 5-Hydroxyindoleacetate [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.4

—

80.20

—

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

0.00

-0.00

0.0

2.2

—

(4146454) Self-monitoring of blood glucose

0.00

-0.00

0.0

3.0

—

(40766048) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum by Immunoassay

0.00

-0.00

0.0

1.5

—

(3022803) Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

-0.00

0.0

3.0

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

0.95

-0.00

3.7

2.7

25.50

32.57

u/l

—

(3045066) Thymidine kinase [Enzymatic activity/volume] in Serum

0.00

-0.00

0.0

1.5

—

16.77

—

(3019897) Erythrocyte distribution width [Ratio] by Automated count

0.00

-0.00

0.0

2.2

—

14.17

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

-0.00

0.0

2.2

—

(3051611) Lipemic interference index of Serum or Plasma

0.00

-0.00

0.0

3.1

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

-0.00

0.0

1.1

—

(3000034) Microalbumin [Mass/volume] in Urine

0.00

-0.00

0.0

5.0

—

41.94

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

(3029075) Extractable nuclear Ab panel - Serum

0.00

-0.00

0.0

1.0

—

(3051651) Icteric interference index of Serum or Plasma

0.00

-0.00

0.0

3.2

—

(3003245) Complement C1 esterase inhibitor [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

0.31

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

-0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint L12_PSORI_ACRODERM and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_PSORI_ACRODERM.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: L12_PSORI_ACRODERM – Acrodermatitis continua

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Acrodermatitis continua

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints